Azenta
Provides sample-management products and multiomics services for life-sciences research.
Something off on this page? Send us feedback.
Profile
Sells sample repository services, automated storage systems, cryogenic tools, consumables, and GENEWIZ multiomics services to life-sciences customers. Continuing operations center on Sample Management Solutions and Multiomics, while the B Medical exit remains an unresolved portfolio simplification.
Provides life-sciences sample management and multiomics services through its continuing segments, Sample Management Solutions and Multiomics. The portfolio includes sample repository services, automated stores, cryogenic systems, automated sample tubes, consumables, instruments, controlled-rate thawing devices, gene sequencing, and gene synthesis.
Customer exposure is more U.S.-weighted than international, with work also outside the United States. Pharmaceutical, biotechnology, and life-sciences research institutions use the platform for sample integrity from procurement and storage through analysis and data support.
The current business is the Brooks Automation successor after the semiconductor automation sale and the Azenta name and ticker change. Continuing performance depends on core segment execution, multiomics demand, acquisition integration, and resolution of the B Medical Systems exit.
Company facts
Categories
Key statistics
Year to date −1.3% · Average volume (30d) 710.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Feb 5, 2026 | Evercore ISI | Target | $50 | $45 | ||
| Jan 5, 2026 | Evercore ISI | Target | $33 | $50 | ||
| Jan 5, 2026 | Evercore ISI Group | Upgrade | In Line | Outperform | ||
| Dec 19, 2025 | Needham | Reiterate | Buy | $78 | $44 | |
| Nov 25, 2025 | Raymond James | Reiterate | Outperform | $45 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q3 FY26 | $0.11 | $0.16 | +40.6% | $149.3M | $161.2M | +8.0% | +5.61% |
| May 6, 2026Q2 FY26 | $0.10 | −$0.04 | −140.0% | $148.3M | $144.8M | −2.4% | +1.03% |
| Feb 4, 2026Q1 FY26 | $0.11 | $0.09 | −18.2% | $147.1M | $148.6M | +1.1% | −2.25% |
| Nov 21, 2025Q4 FY25 | $0.19 | $0.21 | +10.8% | $156.2M | $159.2M | +1.9% | +5.19% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $143.4M | $143.9M | $159.2M | $148.6M | $144.8M | $161.2M | |
| Gross profit | $65.9M | $67.8M | $72.3M | $63.7M | $62.0M | $72.4M | |
| Operating income | −$7.4M | $1.6M | $2.9M | −$4.9M | −$15.3M | −$4.2M | |
| Net income | −$40.5M | −$52.8M | $50.9M | −$15.4M | −$160.8M | $2.5M | |
| Diluted EPS | −$0.88 | −$1.15 | $1.02 | −$0.34 | −$3.49 | $0.05 | |
| Gross margin | 45.9% | 47.1% | 45.4% | 42.9% | 42.8% | 44.9% | |
| Operating margin | -5.2% | 1.1% | 1.8% | -3.3% | -10.6% | -2.6% |
Fiscal years (4-quarter sums)FY21 $513.7M · FY22 $555.5M · FY23 $665.1M · FY24 $573.0M · FY25 $594.0M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $325.8M · Total debt $54.0M · Total assets $1.88B · Shareholders' equity $1.51B
Dividends
Raised for 9 straight years.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Dec 2, 2021 | Dec 3 | Dec 23 | $0.10 | |
| Sep 2, 2021 | Sep 3 | Sep 24 | $0.10 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 46.09M · Float 40.66M · 88.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.53M | 16.34% | 13F | Aug 7, 2026 |
| Politan Capital Management LP | 4.62M | 10.03% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 2.49M | 5.41% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.87M | 4.06% | 13F | Aug 13, 2026 |
| State Street Corp | 1.86M | 4.04% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 31, 2026 | Ephraim Starr | officer: SVP, Gen Counsel & Secretary | +335 | $24.17 |
| May 18, 2026 | William L. Cornog | director | +10,000 | $16.38 |
| May 16, 2025 | William L. Cornog | director | +100 | $26.50 |
| May 19, 2025 | William L. Cornog | director | +4,152 | $26.98 |
| May 20, 2025 | William L. Cornog | director | +2,748 | $27.37 |
Peers
- Thermo Fisher Scientific
Broad biobanking, consumables, and genomic-tools rival
- Labcorp
Clinical-trial biorepository and sample-management services rival
- Twist Bioscience
Synthetic DNA and NGS-tools specialist
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Azenta | $32.95 | −0.03% | $1.52B | — | 57.1 | 2.5 | +12.0% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Twist Bioscience | $141.01 | −0.20% | $8.80B | — | — | 20.4 | +23.3% |
| Median | 30.6 | 20.7 | 5.0 | +10.5% |